217 related articles for article (PubMed ID: 37771787)
1. A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to
Waldeck K; Van Zuylekom J; Cullinane C; Gulati T; Simpson KJ; Tothill RW; Blyth B; Hicks RJ
Theranostics; 2023; 13(14):4745-4761. PubMed ID: 37771787
[TBL] [Abstract][Full Text] [Related]
2. Enhancing the anti-tumour activity of
Cullinane C; Waldeck K; Kirby L; Rogers BE; Eu P; Tothill RW; Hicks RJ
Sci Rep; 2020 Jun; 10(1):10196. PubMed ID: 32576907
[TBL] [Abstract][Full Text] [Related]
3. Peptide Receptor Radionuclide Therapy with
Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS
J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of
Shah RG; Merlin MA; Adant S; Zine-Eddine F; Beauregard JM; Shah GM
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435224
[TBL] [Abstract][Full Text] [Related]
5. Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach.
Gordon S; Chan DLH; Bernard EJ; Eslick ME; Willowson KP; Roach PJ; Engel AF; Maher R; Clarke SJ; Agarwal V; Yasmin L; De Silva M; Mascall S; Conner A; Nevell D; Pavlakis N; Bailey DL
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7717-7728. PubMed ID: 37004598
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
7. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.
Adant S; Shah GM; Beauregard JM
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):907-921. PubMed ID: 31492995
[TBL] [Abstract][Full Text] [Related]
8. DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy
Reuvers TGA; Verkaik NS; Stuurman D; de Ridder C; Groningen MCC; de Blois E; Nonnekens J
Theranostics; 2023; 13(10):3117-3130. PubMed ID: 37351169
[No Abstract] [Full Text] [Related]
9. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
[TBL] [Abstract][Full Text] [Related]
10. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib.
Nonnekens J; van Kranenburg M; Beerens CE; Suker M; Doukas M; van Eijck CH; de Jong M; van Gent DC
Theranostics; 2016; 6(11):1821-32. PubMed ID: 27570553
[TBL] [Abstract][Full Text] [Related]
12. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
13. Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response.
Feijtel D; Doeswijk GN; Verkaik NS; Haeck JC; Chicco D; Angotti C; Konijnenberg MW; de Jong M; Nonnekens J
Theranostics; 2021; 11(2):491-505. PubMed ID: 33391488
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy.
Evans JS; Beaumont J; Braga M; Masrour N; Mauri F; Beckley A; Butt S; Karali CS; Cawthorne C; Archibald S; Aboagye EO; Sharma R
Eur J Cancer; 2022 Nov; 176():110-120. PubMed ID: 36208569
[TBL] [Abstract][Full Text] [Related]
15. Analysis of 177Lu-DOTA-octreotate therapy-induced DNA damage in peripheral blood lymphocytes of patients with neuroendocrine tumors.
Denoyer D; Lobachevsky P; Jackson P; Thompson M; Martin OA; Hicks RJ
J Nucl Med; 2015 Apr; 56(4):505-11. PubMed ID: 25722453
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs).
Mirvis E; Toumpanakis C; Mandair D; Gnanasegaran G; Caplin M; Navalkissoor S
Lung Cancer; 2020 Dec; 150():70-75. PubMed ID: 33075738
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of radiation safety of the newly established national New Zealand 177-Lutetium (177-Lu or Lutate) Peptide Receptor Radiation Therapy (PRRT) service, a palliative treatment for patients with metastatic neuroendocrine tumours.
Davidson J; Hull A; Mead T; Lunt B; Stewart A
J Med Imaging Radiat Sci; 2022 Jun; 53(2 Suppl):S22-S30. PubMed ID: 35437188
[No Abstract] [Full Text] [Related]
18. Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.
Lewin J; Cullinane C; Akhurst T; Waldeck K; Watkins DN; Rao A; Eu P; Mileshkin L; Hicks RJ
Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):25-32. PubMed ID: 25125202
[TBL] [Abstract][Full Text] [Related]
19. Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
Kesavan M; Turner JH
Cancer Biother Radiopharm; 2016 Aug; 31(6):189-98. PubMed ID: 27419665
[TBL] [Abstract][Full Text] [Related]
20. Lutetium-labelled peptides for therapy of neuroendocrine tumours.
Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
